Chengdu Pioneer and Kangzhe Pharmaceutical have reached a cooperation agreement to leverage the DEL and HAILO platforms to empower the development of multi-target innovative drugs
February 2, 2026
Source: https://finance.eastmoney.com/a/202601303636285775.html
31
According to Chengdu Pioneer...According to reports, Chengdu Pioneer recently signed a cooperation agreement with a subsidiary of Kangzhe Pharmaceutical Holdings Limited (hereinafter referred to as " Kangzhe Pharmaceutical "). Chengdu Pioneer will provide Kangzhe Pharmaceutical with innovative drugs targeting multiple specific targets.The company provides development services. Chengdu Pioneer will rely on its DNA-encoded compound library (DEL) technology platform and Qualcomm...HAILO, an AI-driven molecular optimization platform, provides Kangzhe Pharmaceuticals with a one-stop development service from target validation to preclinical compound candidates (PCCs). This initiative aims to efficiently generate drug candidates with "first-in-class" (FIC) or "best-in-class" (BIC) potential.
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Driven by drugs for lowering blood sugar and losing weight, the export value of Chinese Western medicine preparations has reached a record high February 2, 2026
- J&J’s subcutaneous monoclonal antibody combination therapy receives further FDA approval; Autoimmune CAR-T therapy granted FDA Breakthrough Therapy Designation February 2, 2026
- Why is the development of AI-based antiviral drugs a niche field yet a necessity? February 1, 2026
- Pakistan issues final antidumping ruling on Chinese cephalosporin February 1, 2026
- Samsung Biotech “Soars” February 1, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
